as 10-24-2025 3:52pm EST
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 2.2B | IPO Year: | 2019 |
| Target Price: | $22.31 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.16 - $15.06 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ETNB Breaking Stock News: Dive into ETNB Ticker-Specific Updates for Smart Investing
Simply Wall St.
24 days ago
GlobeNewswire
25 days ago
Insider Monkey
a month ago
GlobeNewswire
5 months ago
GlobeNewswire
5 months ago
Insider Monkey
5 months ago
GlobeNewswire
6 months ago
GlobeNewswire
6 months ago
The information presented on this page, "ETNB 89bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.